7.43
7.43 (0%)
As of Apr 17, 2025
Sage Therapeutics, Inc. [SAGE]
Source:
Company Overview
Sage Therapeutics, Inc. is a biopharmaceutical company with a mission to pioneer solutions to deliver life-changing brain health medicines, so every person can thrive. Alongside our commercial product for the treatment of postpartum depression, we are advancing a portfolio of internally discovered novel chemical entities with the potential to become differentiated treatments designed to improve brain health by primarily targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA.
| Country | United States |
| Headquarters | cambridge, massachusetts |
| Phone Number | 617-299-8380 |
| Industry | manufacturing |
| CEO | Barry E. Greene |
| Website | www.sagerx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $41.2 |
| Operating Profit | $-432.4 |
| Net Income | $-400.7 |
| Net Cash | $10.1 |
Profit Ratios
| Gross Margin | $31.8 |
| Operating Margin | -1,048.4 |
| Profit as % of Revenues | -7.9% |
| Profit as % of Assets | -56.1% |
| Profit as % of Stockholder Equity | -86.2% |
Management Effectiveness
| Return on Equity | -86.2% |
| Return on Assets | -73.2% |
| Turnover Ratio | 5.8% |
| EBITA | $-432.4 |
Balance Sheet and Cash Flow Measures
| Total Assets | $547.2 |
| Total Liabilities | $82.1 |
| Operating Cash Flow | $-267.2 |
| Investing Cash Flow | $266.7 |
| Financing Cash Flow | $10.7 |
